Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Vioxx Gains 60,000 Scripts Each Week; $92 Mil. In U.S. Sales To Date

Executive Summary

Nearly half of new Vioxx (refecoxib) scripts are for newly-diagnosed osteoarthritis patients or patients switching to a prescription medication from an over-the-counter treatment, Merck Investor Relations Director Laura Jordan said during a second quarter earnings teleconference July 23.

You may also be interested in...



Searle Celebrex Rxs Climb 5%; Merck Dental Work Bolsters Vioxx New Rxs

Celebrex refills are helping Searle weather a 10% downturn in new scripts in the third quarter and to maintain the COX-2 inhibitor's position in the valuable chronic use market, Searle CEO Alan Heller said during an Oct. 27 presentation to the CIBC World Markets Health Care Conference in New York City.

Searle Celebrex Rxs Climb 5%; Merck Dental Work Bolsters Vioxx New Rxs

Celebrex refills are helping Searle weather a 10% downturn in new scripts in the third quarter and to maintain the COX-2 inhibitor's position in the valuable chronic use market, Searle CEO Alan Heller said during an Oct. 27 presentation to the CIBC World Markets Health Care Conference in New York City.

Merck Developing Singulair/Loratadine Combination For Asthma

Combining Singulair and loratadine, the active ingredient in Claritin, for asthma could result in a 3%-4% increase in efficacy, Merck Research Labs President Edward Scolnick told securities analysts Dec. 9 in Whitehouse Station, N.J.

UsernamePublicRestriction

Register

PS034560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel